Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria

International Journal of Antimicrobial Agents

Volumn 28, Issue 1, 2006, Pages 25-35

  Behra Miellet, J ^a   Dubreuil, L ^a   Calvet, L ^a  

^a UNIV LILLE   (France)

Author keywords

Anaerobes; Carbapenems; Ertapenem; MIC determination

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOXITIN; CLINDAMYCIN; ERTAPENEM; IMIPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; GRAM POSITIVE COCCI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVOTELLA; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BETA-LACTAMS; DRUG EVALUATION, PRECLINICAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS;

EID: 33745205613     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.01.011     Document Type: Article

References (45)

1. Shah P.M., and Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 52 (2003) 538-542
2. Legua P., Lema J., Moll J., et al. Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin Ther 24 (2002) 434-444
3. Musson D.G., Majumdar A., Birk K., et al. Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob Agents Chemother 47 (2003) 1732-1735
4. Nix D.E., Majumdar A.K., and DiNubile M.J. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 53 Suppl. 2 (2004) ii23-ii28
5. Sundelof J.G., Hajdu R., Gill C.J., Thompson R., Rosen H., and Kropp H. Pharmacokinetics of L-749345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother 41 (1997) 1743-1748
6. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y., and Tyrrell K.L. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 44 (2000) 23-94
7. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K., and Fernandez H. Comparative in vitro activities of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J Antimicrob Chemother 48 (2001) 641-651
8. Aldridge K.E., and O'Brien M. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol 40 (2002) 4349-4352
9. Hoellman D.B., Kelly L.M., Credito K., et al. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother 46 (2002) 220-224
10. Pelak B.A., Citron D.M., Motyl M., Goldstein E.J.C., Woods G.L., and Teppler H. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J Antimicrob Chemother 50 (2002) 735-741
11. Piérard D., Wybo I., Vandoorslaer K., Roebben E., Rosseel P., and Lauwers S. In vitro activity of ertapenem against anaerobes isolated from the respiratory tract. Pathol Biol 51 (2003) 508-511
12. Reynolds R., Potz N., Colman M., Williams A., Livermore D., MacGowan A, and BSAC Extended Working Party on Bacteraemia Resistance Surveillance. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 53 (2004) 1018-1032
13. Wexler H.M. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 53 Suppl. 2 (2004) ii11-ii21
14. Paterson D.L., Rossi F., Baquero F., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55 (2005) 965-973
15. Decousser J.W., Methlouthi I., Pina P., Allouch P., and ColBVH Study Group. In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains. J Antimicrob Chemother 55 (2005) 396-398
16. Tice A.D. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 53 Suppl. S2 (2004) ii83-ii86
17. Fuchs P.C., Barry A.L., and Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 45 (2001) 1915-1918
18. Livermore D.M., Carter M.W., Bagel S., et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 45 (2001) 1860-1867
19. Cunha B.A. Ertapenem: a review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today (Barc) 38 (2002) 195-213
20. Yellin A.E., Hassett J.M., Fernandez A., et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents 20 (2002) 165-173
21. Livermore D.M., Sefton A.M., and Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 52 (2003) 331-344
22. Woods G.L., Isaacs R.D., McCarroll K.A., and Friedland I.R. Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc 51 (2003) 1526-1532
23. Gesser R.M., McCarroll K.A., and Woods G.L. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect 48 (2004) 32-38
24. Marchese A., Gualco L., Schito A.M., Debbia E.A., and Schito G.C. In vitro activity of ertapenem against selected respiratory pathogens. J Antimicrob Chemother 54 (2004) 944-951
25. Livermore D.M., Mushtaq S., and Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 55 (2005) 306-311
26. Zhanel G.G., Johansen C., Embil J.M., et al. Ertapenem: a review of a new carbapenem. Expert Rev Anti Infect Ther 3 (2005) 23-39
27. Laethem T., De Lepeleire I., McCrea J., et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother 47 (2003) 1439-1442
28. Teppler H., Gesser R.M., Friedland I.R., et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 53 Suppl. S2 (2004) ii75-ii81
29. Solomkin J.S., Yellin A.E., Rotstein O.D., et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomised comparative phase III trial. Ann Surg 237 (2003) 235-245
30. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved Standard M11-A5. 5th ed. (2001), NCCLS, Wayne, PA
31. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved Standard M11-A6. 6th ed. (2004), NCCLS, Wayne, PA
32. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved Standard M11-A4. 4th ed. (1997), NCCLS, Wayne, PA
33. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. 3rd ed. (1993), NCCLS, Villanova, PA
34. National Committee for Clinical Laboratory Standards. Reference dilution procedure for antimicrobial testing of anaerobic bacteria. Approved standard M-11T (1979), NCCLS, Villanova, PA
35. National Committee for Clinical Laboratory Standards. Methods for antimicrobial testing of anaerobic bacteria. Approved standard M11-A2. 2nd ed. (1990), NCCLS, Villanova, PA
36. Jousimies-Somer H., Summanen P., Citron D.M., Jo Baron E., Wexler H.M., and Finegold S.M. Chapters 3-8, appendix D, E, F and references. In: Hoffman S. (Ed). Wadsworth-KTL anaerobic bacteriology manual. 6th ed. (2002), Star Publishing Company, Belmont, CA 43-287
37. Brazier J.S., Citron D.M., and Goldstein E.J.C. A selective medium for Fusobacterium spp. J Appl Bacteriol 71 (1991) 343-346
38. Ericsson H.M., and Sherris J.C. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol 217 Suppl. (1971) S1-S90
39. Members of the SFM Antibiogram Committee. Comité de l'Antibiogramme de la Société Française de Microbiologie-communiqué 2005. Edition de Janvier 2005. Paris, France: Société Française de Microbiologie; 2005.
40. Mory F., Loczniewski A., Bland S., et al. Survey of anaerobic susceptibility patterns: a French multicentre study. Int J Antimicrob Agents 10 (1998) 229-236
41. Behra-Miellet J., Calvet L., and Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents 22 (2003) 28-34
42. Odou M.F., Singer E., Romond M.B., and Dubreuil L. Isolation and characterization of a porin-like protein of 45 kilodaltons from Bacteroides fragilis. FEMS Microbiol Lett 166 (1998) 347-354
43. Behra-Miellet J., Calvet L., and Dubreuil L. A Bacteroides thetaiotamicron porin that could take part in resistance to β-lactams. Int J Antimicrob Agents 24 (2004) 135-143
44. Goldstein E.J.C., Citron D.M., Merriam V., Warren Y., Tyrrell K.L., and Gesser R.M. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin Infect Dis 35 Suppl. 1 (2002) S119-S125
45. Solomkin J., Teppler H., Graham D.R., et al. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J Antimicrob Chemother 53 Suppl. 2 (2004) ii51-ii57